Washington, DC 20549





Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934


Date of Report (Date of earliest event reported) July 25, 2023


ENDRA Life Sciences Inc. 

(Exact name of registrant as specified in its charter)







(State or other jurisdiction

of incorporation)



File Number)


(IRS Employer

Identification No.)


3600 Green Court, Suite 350 Ann Arbor, MI



(Address of principal executive offices)


(Zip Code)


Registrant's telephone number, including area code   (734) 335-0468


(Former name or former address, if changed since last report)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)



Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)



Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))



Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Securities registered pursuant to Section 12(b) of the Act:


Title of each class



Name of each exchange

on which registered

Common stock, par value $0.0001 per share


The Nasdaq Stock Market LLC


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).


Emerging growth company


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐





Item 8.01. Other Events


On July 25, 2023, ENDRA Life Sciences Inc. (the “Company”) reconvened its 2023 Annual Meeting of Stockholders (the “Annual Meeting”), as previously scheduled, and adjourned the Annual Meeting until Wednesday, August 9, 2023 at 10:00 am, Eastern Time due to a lack of quorum. The Annual Meeting had previously been commenced July 6, 2023 and adjourned due to a lack of quorum. On both July 6, 2023 and July 25, 2023, the Annual Meeting was adjourned to allow the Company’s stockholders additional time to vote on the proposals described in the Company’s proxy statement for the Annual Meeting.


The reconvened Annual Meeting will be held virtually at the following link www.virtualshareholdermeeting.com/NDRA2023. Stockholders who have already voted do not need to recast their votes. Proxies previously submitted in respect of the Annual Meeting will be voted at the adjourned Annual Meeting unless properly revoked. During the period of the adjournment, the Company will continue to solicit votes from its stockholders with respect to the proposals for the Annual Meeting.


The Company encourages all stockholders of record as of the close of business on May 12, 2023 who have not yet voted, to do so by Tuesday, August 8, 2023 at 11:59 pm Eastern Time. Notwithstanding the foregoing, any votes properly received before the close of the Annual Meeting on August 9, 2023, will be accepted.


Additional Information and Where to Find It


This document may be deemed to be solicitation material in respect of the Annual Meeting to be held on August 9, 2023. As discussed in the press release filed as an exhibit to this filing, the Company previously filed a definitive proxy statement with the United States Securities and Exchange Commission (the “SEC”) on May 24, 2023. BEFORE MAKING ANY VOTING DECISIONS, SECURITY HOLDERS ARE URGED TO READ THE DEFINITIVE PROXY STATEMENT AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC, BECAUSE THEY CONTAIN IMPORTANT INFORMATION ABOUT THE ADJOURNED MEETING. The definitive proxy statement has been mailed to stockholders who are entitled to vote at the Annual Meeting. No changes have been made in the proposals to be voted on by stockholders at the Annual Meeting. The Company’s proxy statement and any other materials filed by the Company with the SEC can be obtained free of charge at the SEC’s website at https://www.sec.gov/Archives/edgar/data/1681682/000165495423007157/ndra_def14a.htm.


Participants in the Solicitation


The Company and its directors and executive officers and other employees may be deemed to be participants in the solicitation of proxies in respect of the Annual Meeting.








Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.



ENDRA Life Sciences Inc.


July 25, 2023





/s/ Francois Michelon




Francois Michelon




President and Chief Executive Officer






Jul. 25, 2023
Cover [Abstract]  
Entity Registrant Name ENDRA Life Sciences Inc.
Entity Central Index Key 0001681682
Document Type 8-K
Amendment Flag false
Entity Emerging Growth Company false
Document Period End Date Jul. 25, 2023
Entity Incorporation State Country Code DE
Entity Tax Identification Number 26-0579295
Written Communications false
Soliciting Material true
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Entity File Number 001-37969
Entity Address Address Line 1 3600 Green Court
Entity Address Address Line 2 Suite 350
Entity Address City Or Town Ann Arbor
Entity Address State Or Province MI
Entity Address Postal Zip Code 48105
City Area Code 734
Local Phone Number 335-0468
Security 12b Title Common stock, par value $0.0001 per share
Trading Symbol NDRA
Security Exchange Name NASDAQ

Historical Stock Chart
From Jan 2024 to Feb 2024 Click Here for more ENDRA Life Sciences Charts.
Historical Stock Chart
From Feb 2023 to Feb 2024 Click Here for more ENDRA Life Sciences Charts.